Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CALR mutation profile in Irish patients with myeloproliferative neoplasms.

Hematology/oncology and stem cell therapy - 1 Sept 2016

Haslam Karl, Conneally Eibhlin, Flynn Catherine M, Cahill Mary R, Gilligan Oonagh, O'Shea Derville, Langabeer Stephen E

Abstract excerpt

Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Neoplasms

Share to Calreticulin

Share to CALR gene

Share to Ireland

Share to Mutation

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 27352261
DOI: 10.1016/j.hemonc.2016.05.002

Genes

CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CALR mutation profile in Irish patients with myeloproliferative neoplasms.PMID 27352261Read ↗

Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations.Semantic proximity Read ↗

The different variant allele frequencies of type I/type II mutations and the distinct molecular landscapes in CALR-mutant essential thrombocythaemia and primary myelofibrosis.Semantic proximity Read ↗

The characteristics of CALR mutations in myeloproliferative neoplasms: a clinical experience from a tertiary care center in Qatar and a literature review.Semantic proximity Read ↗

CALR type 1 mutations are associated with an increased incidence of myelofibrosis in young male patients.Semantic proximity Read ↗

Myeloproliferative neoplasms with a low (<5%) CALR mutation allele burden.Semantic proximity Read ↗

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.Semantic proximity Read ↗

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.Semantic proximity Read ↗

Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Semantic proximity Read ↗

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.Semantic proximity Read ↗

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.Semantic proximity Read ↗

Calreticulin mutation profile in Indian patients with primary myelofibrosis.Semantic proximity Read ↗

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.